LUCD
What one share of Lucid Diagnostics holds
Surgical and Medical Instruments and Apparatus
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”).
Lucid Diagnostics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.04 |
|---|---|
| Profit | −$0.46 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.34 |
| Cash and investments | $0.18 |
| Book value | $0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.59 | — | −$0.40 | — | −$0.96 |
| 2021 | $0.03 | −$1.51 | $0.05 | −$1.00 | — | $1.57 |
| 2022 | $0.01 | −$1.55 | $0.09 | −$0.91 | — | $0.57 |
| 2023 | $0.06 | −$1.26 | — | −$0.79 | — | −$0.05 |
| 2024 | $0.09 | −$1.05 | $0.01 | −$0.88 | — | $0.09 |
| 2025 | $0.05 | −$0.69 | $0.00 | −$0.46 | — | $0.08 |